Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $26 from $23 and keeps a Buy rating on the shares following the company’s Investor Day and Q4 earnings results. Revenue for Q4 was $11.6M, beating Street expectations of $10.5M, with GAAP EPS at ($0.02) vs. ($0.00). Management provided 2025 guidance, targeting an $80M annual revenue run rate by year-end and a path to exceeding $100M in the near term, driven by acquisitions, Alkindi growth, and ET-400 launch, the firm notes. Investor Day showcased significant revenue potential, with management highlighting nearly $500M in peak sales from the portfolio and pipeline, adds Craig-Hallum.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Promising Growth Prospects and Strategic Initiatives Justify Buy Rating for Eton Pharmaceuticals
- Eton Pharmaceuticals Reports Record Q4 Revenue Growth
- Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions
- Eton Pharmaceuticals to Host Virtual Investor Day
- Morning Movers: Sarepta slumps after death following Elevidys use